Will Viking Therapeutics be acquired before 2027?

Viking Therapeutics sits at the intersection of the hottest pharmaceutical trend in a generation and the specific deal profile that major pharma acquirers have historically targeted — a clinical-stage asset with strong mid-stage data, a digestible market cap, and a founder-CEO who built the company as a GLP-1 challenger from the ground up. VK2735 is the entire thesis. A GLP-1/GIP dual agonist in both injectable and oral formulations, with Phase 2 weight-loss data competitive with the established players, positions Viking as exactly the kind of asset that Novo Nordisk and Eli Lilly's competitors need to close the obesity gap. Pfizer, AstraZeneca, Roche, and others watching the GLP-1 revolution reshape pharmaceutical revenue streams have limited organic options — acquiring a late-stage asset is faster than building one. The 38-40% YES pricing reflects the deal logic being genuinely compelling without being inevitable. Viking's roughly $600 million in cash and management's explicit statement that they can operate into 2028 removes forced-sale pressure — a company that doesn't need to sell has leverage to hold out for a premium that meets their standalone valuation case. Wall Street price targets clustering around three times the current share price if VK2735 continues executing creates a high bar for any acquirer to clear with a bid that management and shareholders would accept. The CordenPharma manufacturing deal is the most analytically interesting recent signal. Prepaying for API and device supply over three years reads either as "going it alone" or as "de-risking supply chain whether or not we're acquired" — management's framing supports the latter, but the investment reflects genuine optionality rather than pure acquisition preparation. The GLP-1 space's crowding is the acquirer's dilemma. Phase 3 success, safety at scale, manufacturing ramp, and payer behavior in a market already dominated by two entrenched giants all require significant post-acquisition investment beyond the purchase price. Bottom line: Viking is a legitimate acquisition target in a sector where strategic logic for a deal is clear. The 38-40% YES pricing correctly reflects that "could be bought" and "will be bought by 2027" are different analytical claims. Watch any Phase 3 data readouts for VK2735 as the specific catalyst most likely to either accelerate acquirer interest or update the standalone valuation that currently gives management room to stay independent.